Dex on Microcirculation in SS-A Double-blinded Study

The Effect of Dexmedetomidine on Microcirculation in Septic Shock- A Double-blinded Study

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02612181

Enrollment

Registered

2015-11-23

Start date

2016-01-31

Completion date

2017-12-31

Last updated

2017-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Keywords

dexmedetomidine, microcirculation, septic shock

Brief summary

The investigators preliminary study showed that dexmedetomidine might improve microcirculation in septic shock patients. To test this effect, the investigators will conduct double-blinded study.

Detailed description

Dexmedetomidine is a highly selective α2-adrenoreceptor agonist for sedation of adult critically ill patients which exhibits sedative and analgesic effects. Recent studies suggest that dexmedetomidine to restore adrenergic vasoconstrictor responsiveness in septic shock, and prevents alterations of pain rat model intestinal microcirculation Induced by surgical stress，even it can reduce the mortality of endotoxemic rats and patients with severe sepsis. The investigators preliminary study showed that dexmedetomidine might improve microcirculation in septic shock patients. To test this effect, the investigators will conduct double-blinded study.

Interventions

DRUGDexmedetomidine for dexmedetomidine group

The effect of dex and placebo for sedation on microcirculation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Septic shock patients despite early goal directed therapy * Agree to participate this study

Exclusion criteria

* Age\< 18 * Pregnancy * Bradycardia (HR\<55bpm) * Systolic Blood Pressure \< 80 mmHg / Mean arterial pressure \< 50 mmHg on maximal support * Death imminent * Unlikely to survive 90 days * Acute liver failure * Dementia * High-grade block in the absence of a functioning pacemaker.

Design outcomes

Primary

Measure	Time frame	Description
Microcirculatory function as assessed by Microvascular flow index	30 minutes	sedation for 30 minutes then monitor the microcirculation

Countries

China

Contacts

Primary ContactJingyuan Xu, M.D.

xujingyuanmail@163.com862586232550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026